Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome

Critical Care

Volumn 17, Issue 5, 2013, Pages

  Ware, Lorraine B ^a   Koyama, Tatsuki ^a   Zhao, Zhiguo ^a   Janz, David R ^a   Wickersham, Nancy ^a   Bernard, Gordon R ^a   May, Addison K ^a   Calfee, Carolyn S ^b   Matthay, Michael A ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOPOIETIN 2; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CLUB CELL SECRETORY PROTEIN 16; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; PEPTIDES AND PROTEINS; PROCOLLAGEN PEPTIDE III; SECRETORY PROTEIN; STROMELYSIN; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM INJURY; FEMALE; FIBROBLAST; HUMAN; INFLAMMATION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEPSIS; AGED; BLOOD; COMPLICATION; DIFFERENTIAL DIAGNOSIS; INTENSIVE CARE; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INTENSIVE CARE; LUNG INJURY; MALE; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84886732783     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13080     Document Type: Article

References (33)

1. Ware LB, Matthay MA. Medical progress: the acute respiratory distress syndrome. N Engl J Med 2000, 342:1334-1349. 10.1056/NEJM200005043421806, 10793167.
2. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:2526-2533.
3. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824. 10.1164/ajrccm.149.3.7509706, 7509706.
4. Barnett N, Ware LB. Biomarkers in acute lung injury-marking forward progress. Crit Care Clin 2011, 27:661-683. 10.1016/j.ccc.2011.04.001, 3134784, 21742222.
5. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012, 122:2731-2740. 10.1172/JCI60331, 3408735, 22850883.
6. Fremont RD, Koyama T, Calfee CS, Wu W, Dossett LA, Bossert FR, Mitchell D, Wickersham N, Bernard GR, Matthay MA, May AK, Ware LB. Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis. J Trauma 2010, 68:1121-1127. 10.1097/TA.0b013e3181c40728, 3347639, 20038857.
7. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010, 137:288-296. 10.1378/chest.09-1484, 2816641, 19858233.
8. Calfee CS, Ware LB, Glidden DV, Eisner MD, Parsons PE, Thompson BT, Matthay MA. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med 2011, 39:711-717. 10.1097/CCM.0b013e318207ec3c, 3260884, 21283009.
9. Calfee CS, Eisner MD, Ware LB, Thompson BT, Parsons PE, Wheeler AP, Korpak A, Matthay MA. Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med 2007, 35:2243-2250. 2765812, 17944012.
10. O'Neal HR, Koyama T, Koehler EA, Siew E, Curtis BR, Fremont RD, May AK, Bernard GR, Ware LB. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011, 39:1343-1350. 10.1097/CCM.0b013e3182120992, 3102130, 21336116.
11. Siew ED, Ikizler TA, Gebretsadik T, Shintani A, Wickersham N, Bossert F, Peterson JF, Parikh CR, May AK, Ware LB. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol 2010, 5:1497-1505. 10.2215/CJN.09061209, 2924408, 20558561.
12. Siew ED, Ware LB, Gebretsadik T, Shintani A, Moons KG, Wickersham N, Bossert F, Ikizler TA. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009, 20:1823-1832. 10.1681/ASN.2008070673, 2723988, 19628673.
13. LeGall J, Lemshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.1993.03510240069035, 8254858.
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
15. Bone R, Balk R, Cerra F, Dellinger R, Fein A, Knaus W, Schein R, Sibbald W. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101:1644-1655. 10.1378/chest.101.6.1644, 1303622.
16. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of the SpO2/FiO2 ratio and the PaO2/FiO2 ratio in patients with acute lung injury or acute respiratory distress syndrome. Chest 2007, 132:410-417. 10.1378/chest.07-0617, 17573487.
17. Ware LB, Matthay MA. Clinical practice, acute pulmonary edema. N Engl J Med 2005, 353:2788-2796. 10.1056/NEJMcp052699, 16382065.
18. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012, 185:67-76. 10.1164/rccm.201101-0058OC, 3262037, 22016448.
19. Yamashita CM, Dolgonos L, Zemans RL, Young SK, Robertson J, Briones N, Suzuki T, Campbell MN, Gauldie J, Radisky DC, Riches DW, Yu G, Kaminski N, McCulloch CA, Downey GP. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol 2011, 179:1733-1745. 10.1016/j.ajpath.2011.06.041, 3181358, 21871427.
20. Bradley LM, Douglass MF, Chatterjee D, Akira S, Baaten BJ. Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling. PLoS Pathog 2012, 8:e1002641. 10.1371/journal.ppat.1002641, 3320598, 22496659.
21. Rubenfeld GD. Epidemiolgy of acute lung injury. Crit Care Med 2003, 31:S276-S284. 10.1097/01.CCM.0000057904.62683.2B, 12682453.
22. Cheng IW, Ware LB, Greene KE, Nuckton TJ, Eisner MD, Matthay MA. Prognostic value of surfactant proteins A and D in patients with acute lung injury. Crit Care Med 2003, 31:20-27. 10.1097/00003246-200301000-00003, 12544988.
23. Eisner MD, Parsons P, Matthay MA, Ware L, Greene K. the ARDS Network Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury. Thorax 2003, 58:983-988. 10.1136/thorax.58.11.983, 1746524, 14586055, the ARDS Network.
24. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, Mednick G, Matthay ZA, Matthay MA. receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006, 173:1008-1015. 10.1164/rccm.200509-1477OC, 2662912, 16456142.
25. Calfee CS, Ware LB, Eisner MD, Parsons PE, Thompson BT, Wickersham N, Matthay MA. Plasma receptor for advanced glycation end-products and clinical outcomes in acute lung injury. Thorax 2008, 63:1083-1089. 10.1136/thx.2008.095588, 2764528, 18566109.
26. Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009, 135:1440-1447. 10.1378/chest.08-2465, 2716712, 19188556.
27. Determann RM, Millo JL, Waddy S, Lutter R, Garrard CS, Schultz MJ. Plasma CC16 levels are associated with development of ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med 2009, 9:49. 10.1186/1471-2466-9-49, 2794841, 19958527.
28. Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation and repair. Am J Physiol Lung Cell Mol Physiol 2002, 282:L924-L940.
29. Cross LJ, O'Kane CM, McDowell C, Elborn JJ, Matthay MA, McAuley DF. Keratinocyte growth factor in acute lung injury to reduce pulmonary dysfunction-a randomised placebo-controlled trial (KARE): study protocol. Trials 2013, 14:51. 10.1186/1745-6215-14-51, 3620926, 23419093.
30. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013, 187:751-760. 10.1164/rccm.201206-0990OC, 23292883.
31. Zeyed YF, Bastarache JA, Matthay MA, Ware LB. The severity of shock is associated with impaired rates of net alveolar fluid clearance in clinical acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012, 303:L550-L555. 10.1152/ajplung.00190.2012, 3468480, 22821995.
32. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163:1376-1383. 10.1164/ajrccm.163.6.2004035, 11371404.
33. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012, 18:716-725. 10.1038/nm.2678, 22561835.